TY - JOUR
T1 - Acute Myeloid Leukemia, Version 2.2021 Featured Updates to the NCCN Guidelines
T2 - Acute Myeloid Leukemia, Version 2.2021
AU - Pollyea, Daniel A.
AU - Bixby, Dale
AU - Perl, Alexander
AU - Bhatt, Vijaya Raj
AU - Altman, Jessica K.
AU - Appelbaum, Frederick R.
AU - Lima, Marcos De
AU - Fathi, Amir T.
AU - Foran, James M.
AU - Gojo, Ivana
AU - Hall, Aric C.
AU - Jacoby, Meagan
AU - Lancet, Jeffrey
AU - Mannis, Gabriel
AU - Marcucci, Guido
AU - Martin, Michael G.
AU - Mims, Alice
AU - Neff, Jadee
AU - Nejati, Reza
AU - Olin, Rebecca
AU - Percival, Mary Elizabeth
AU - Prebet, Thomas
AU - Przespolewski, Amanda
AU - Rao, Dinesh
AU - Ravandi-Kashani, Farhad
AU - Shami, Paul J.
AU - Stone, Richard M.
AU - Strickland, Stephen A.
AU - Sweet, Kendra
AU - Vachhani, Pankit
AU - Wieduwilt, Matthew
AU - Gregory, Kristina M.
AU - Ogba, Ndiya
AU - Tallman, Martin S.
N1 - Publisher Copyright:
© JNCCN-Journal of the National Comprehensive Cancer Network.
PY - 2021/1
Y1 - 2021/1
N2 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
AB - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regarding factors with prognostic importance, and are intended to aid physicians with clinical decision-making. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who prefer not to receive blood transfusions during treatment.
KW - Adult
KW - Humans
KW - Leukemia, Myeloid, Acute/diagnosis
KW - Mutation
KW - Prognosis
UR - http://www.scopus.com/inward/record.url?scp=85099750763&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000617702700006&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/JNCCN.2021.0002
DO - 10.6004/JNCCN.2021.0002
M3 - Article
C2 - 33406488
SN - 1540-1405
VL - 19
SP - 16
EP - 27
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 1
ER -